Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001193125-26-096584 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-03-06 | 2026-03-04 | TEVA | Daniell Richard | EVP, Europe Commercial | M - OptEx | — | +54.0K | 156.6K | +53% | — |
| DMT | 2026-03-06 | 2026-03-04 | TEVA | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $32.66 | -91.3K | 123.1K | -43% | -$2.98M |
| DMT | 2026-03-06 | 2026-03-04 | TEVA | Daniell Richard | EVP, Europe Commercial | M - OptEx | $0.00 | -54.0K | 40.9K | -57% | $0 |
| DT | 2026-03-06 | 2026-03-04 | TEVA | Daniell Richard | EVP, Europe Commercial | A - Grant | $0.00 | +33.4K | 33.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-04 | M | A | 20,461 | — | 143,588 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Common | Ordinary Shares | 2026-03-04 | S | D | 33,512 | $32.46 | 123,127 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Ordinary Shares | 2026-03-04 | M | A | 33,512 | — | 156,639 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 4 | Common | Ordinary Shares | 2026-03-04 | S | D | 37,372 | $32.95 | 85,755 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.905 to $33.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Common | Ordinary Shares | 2026-03-04 | S | D | 20,461 | $32.46 | 123,127 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 6 | Derivative | Restricted Share Units | 2026-03-04 | M | D | 33,512 | $0.00 | 0 | D | — · — to — | 33,512 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F7) Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. |
| 7 | Derivative | Restricted Share Units | 2026-03-04 | A | A | 33,424 | $0.00 | 33,424 | D | — · — to — | 33,424 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F9) Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. |
| 8 | Derivative | Restricted Share Units | 2026-03-04 | M | D | 20,461 | $0.00 | 40,923 | D | — · — to — | 20,461 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F8) Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. |